Jong Hoon Hyun1, Moo Hyun Kim1, Yujin Sohn1, Yunsuk Cho1, Yae Jee Baek1, Jung Ho Kim1, Jin Young Ahn1, Jun Yong Choi1, Joon Sup Yeom1, Mi Young Ahn2, Eun Jin Kim3, Ji-Hyeon Baek4, Young Keun Kim5, Heun Choi6, Su Jin Jeong7. 1. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro Seodaemun-gu, Seoul, 03722, South Korea. 2. Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea. 3. Department of Infectious Diseases, Ajou University School of Medicine, Suwon, South Korea. 4. Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea. 5. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea. 6. Department of Infectious Disease, National Health Insurance Service Ilsan Hospital, Goyang, South Korea. 7. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro Seodaemun-gu, Seoul, 03722, South Korea. JSJ@yuhs.ac.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with acute respiratory distress syndrome, and corticosteroids have been considered as possible therapeutic agents for this disease. However, there is limited literature on the appropriate timing of corticosteroid administration to obtain the best possible patient outcomes. METHODS: This was a retrospective cohort study including patients with severe COVID-19 who received corticosteroid treatment from March 2 to June 30, 2020 in seven tertiary hospitals in South Korea. We analyzed the patient demographics, characteristics, and clinical outcomes according to the timing of steroid use. Twenty-two patients with severe COVID-19 were enrolled, and they were all treated with corticosteroids. RESULTS: Of the 22 patients who received corticosteroids, 12 patients (55%) were treated within 10 days from diagnosis. There was no significant difference in the baseline characteristics. The initial PaO2/FiO2 ratio was 168.75. The overall case fatality rate was 25%. The mean time from diagnosis to steroid use was 4.08 days and the treatment duration was 14 days in the early use group, while those in the late use group were 12.80 days and 18.50 days, respectively. The PaO2/FiO2 ratio, C-reactive protein level, and cycle threshold value improved over time in both groups. In the early use group, the time from onset of symptoms to discharge (32.4 days vs. 60.0 days, P = 0.030), time from diagnosis to discharge (27.8 days vs. 57.4 days, P = 0.024), and hospital stay (26.0 days vs. 53.9 days, P = 0.033) were shortened. CONCLUSIONS: Among patients with severe COVID-19, early use of corticosteroids showed favorable clinical outcomes which were related to a reduction in the length of hospital stay.
BACKGROUND:Coronavirus disease 2019 (COVID-19) is associated with acute respiratory distress syndrome, and corticosteroids have been considered as possible therapeutic agents for this disease. However, there is limited literature on the appropriate timing of corticosteroid administration to obtain the best possible patient outcomes. METHODS: This was a retrospective cohort study including patients with severe COVID-19 who received corticosteroid treatment from March 2 to June 30, 2020 in seven tertiary hospitals in South Korea. We analyzed the patient demographics, characteristics, and clinical outcomes according to the timing of steroid use. Twenty-two patients with severe COVID-19 were enrolled, and they were all treated with corticosteroids. RESULTS: Of the 22 patients who received corticosteroids, 12 patients (55%) were treated within 10 days from diagnosis. There was no significant difference in the baseline characteristics. The initial PaO2/FiO2 ratio was 168.75. The overall case fatality rate was 25%. The mean time from diagnosis to steroid use was 4.08 days and the treatment duration was 14 days in the early use group, while those in the late use group were 12.80 days and 18.50 days, respectively. The PaO2/FiO2 ratio, C-reactive protein level, and cycle threshold value improved over time in both groups. In the early use group, the time from onset of symptoms to discharge (32.4 days vs. 60.0 days, P = 0.030), time from diagnosis to discharge (27.8 days vs. 57.4 days, P = 0.024), and hospital stay (26.0 days vs. 53.9 days, P = 0.033) were shortened. CONCLUSIONS: Among patients with severe COVID-19, early use of corticosteroids showed favorable clinical outcomes which were related to a reduction in the length of hospital stay.
Authors: John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane Journal: N Engl J Med Date: 2020-10-08 Impact factor: 91.245
Authors: Timotius Ivan Hariyanto; Karunia Valeriani Japar; Felix Kwenandar; Vika Damay; Jeremia Immanuel Siregar; Nata Pratama Hardjo Lugito; Margaret Merlyn Tjiang; Andree Kurniawan Journal: Am J Emerg Med Date: 2020-12-30 Impact factor: 2.469
Authors: Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson Journal: Lancet Date: 2020-03-16 Impact factor: 79.321
Authors: Alberto Cecconi; Pablo Martinez-Vives; Alberto Vera; Cristina Lavilla Olleros; Ana Barrios; Eva Fonseca Aizpuru; Pilar Roquero; Susana Hernandez Muñiz; Maria Jose Olivera; Marianela Ciudad; Ruben Pampin Sanchez; Rosa Fernandez-Madera Martínez; Azucena Bautista-Hernández; Elena García Castillo; Gorane Iturricastillo; Elena Ávalos; Diana Prada Cotado; Alvaro Alejandre de Oña; Eduardo Fernandez Carracedo; Ana Marcos-Jimenez; Ancor Sanz-Garcia; Aranzazu Alfranca; Maurizio Cecconi; Hortensia de La Fuente; Maria Angeles Sanz de Benito; Paloma Caballero; Francisco Sanchez-Madrid; Julio Ancochea; Carmen Suarez; Luis Jesus Jimenez-Borreguero; Fernando Alfonso Journal: Sci Rep Date: 2022-06-02 Impact factor: 4.996
Authors: Khalid Al Sulaiman; Ghazwa B Korayem; Khalid Eljaaly; Ali F Altebainawi; Omar Al Harbi; Hisham A Badreldin; Abdullah Al Harthi; Ghada Al Yousif; Ramesh Vishwakarma; Shorouq Albelwi; Rahaf Almutairi; Maha Almousa; Razan Alghamdi; Alaa Alhubaishi; Abdulrahman Alissa; Aisha Alharbi; Rahmah Algarni; Sarah Al Homaid; Khawla Al Qahtani; Nada Akhani; Abdulaleam Al Atassi; Ghassan Al Ghamdi; Ohoud Aljuhani Journal: Sci Rep Date: 2022-06-13 Impact factor: 4.996
Authors: Faryal Khamis; Salah Al Awaidy; Muna Al Shaaibi; Mubarak Al Shukeili; Shabnam Chhetri; Afra Al Balushi; Sumaiya Al Sulaimi; Amal Al Balushi; Ronald Wesonga Journal: Diseases Date: 2021-12-23